According to a recent LinkedIn post from Aignostics, the company has been selected for the EIC STEP Scale Up program, an equity investment initiative of the European Innovation Council aimed at scaling EU start-ups developing strategically important innovations. The post notes that Aignostics is one of eight companies put forward for investment by the EIC Fund and that it has received the STEP Seal after completing the program’s evaluation process.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests growing institutional validation of Aignostics’ AI-driven precision medicine platform, which targets improvements in drug development and patient outcomes. For investors, inclusion in a selective EU-backed equity initiative may signal enhanced access to growth capital, stronger credibility with biopharma partners, and potential acceleration of the company’s commercialization and clinical collaboration pipeline across Europe and beyond.